Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Laboratory test nomenclature updated in Finland

21 Jun 2023

On June 5, 2023, the updated version of the Finnish laboratory test nomenclature (Laboratoriotutkimusnimikkeistö) was published by the Finnish Institute for Health and Welfare (THL) to come into force on July 1, 2023.

The nomenclature covers studies in clinical chemistry, clinical physiology, clinical microbiology, clinical neurophysiology, genetics, and pathology and is used to unify coding laboratory procedures in Finland. The Laboratory test nomenclature is also used to code the tests in private settings with coverage from the national public payor (KELA).

A total of 138 new codes were introduced in the updated version. Some examples of newly introduced codes are provided below:

  • 6661 Hepatitis C virus, genotyping;
  • 6687 Li-Neuronal glutamate decarboxylase (GAD), antibodies;
  • 6697 S-Phospholipase A2 receptor, antibodies;
  • 6723 P-Enterovirus, nucleic acid (qual);
  • 6730 Multiresistant Gram-negative rods, cultivation.

The letter before the code name indicates the sample type: P - plasma, S - serum, Li – cerebrospinal fluid.

See the full details in Finnish here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.